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Abstract: The recent global pandemic of COVID-19 has predisposed a relatively high number
of patients to acute respiratory distress syndrome (ARDS), which carries a risk of developing
super-infections. Candida species are major constituents of the human mycobiome and the main cause
of invasive fungal infections, with a high mortality rate. Invasive yeast infections (IYIs) are increasingly
recognized as s complication of severe COVID-19. Despite the marked immune dysregulation in
COVID-19, no prominent defects have been reported in immune cells that are critically required
for immunity to Candida. This suggests that relevant clinical factors, including prolonged ICU stays,
central venous catheters, and broad-spectrum antibiotic use, may be key factors causing COVID-19
patients to develop IYIs. Although data on the comparative performance of diagnostic tools are often
lacking in COVID-19 patients, a combination of serological and molecular techniques may present a
promising option for the identification of IYIs. Clinical awareness and screening are needed, as IYIs
are difficult to diagnose, particularly in the setting of severe COVID-19. Echinocandins and azoles are
the primary antifungal used to treat IYIs, yet the therapeutic failures exerted by multidrug-resistant
Candida spp. such as C. auris and C. glabrata call for the development of new antifungal drugs with
novel mechanisms of action.
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1. Introduction
Yeast species belonging to the Candida genus, including Candida albicans, Candida glabrata,
Candida parapsilosis, Candida tropicalis, and Candida krusei, are the most prevalent fungal species
inhabiting various mucosal surfaces, such as the skin and the respiratory, digestive, and urinary
tracts [1,2]. Although being commensal within the human host, Candida species are equipped with
virulence attributes, enabling them to invade when opportunities arise and cause various infections
in humans, especially when the immune system is impaired [2]. Superficial infections, such as skin
disorders; mucosal infections, including oropharyngeal or vulvovaginitis candidiasis; and invasive
candidiasis are established clinical entities of candidiasis [3–8]. Candida is among the most frequently
recovered pathogen in the intensive care unit (ICU), affecting between 6% and 10% of patients, and some
studies have noted an increasing trend for candidemia [9]. The estimated mortality attributed to invasive
candidiasis is 19–40% [10]. This mortality is even higher among ICU patients, approaching 70% [11].
Apart from being associated with excess economic costs and approximately 1.5 million annual
deaths [8], the new landscape of candidemia reveals an increasing incidence of non-albicans Candida
(NAC) species, with intrinsic resistance to antifungals and/or with a propensity to rapidly acquire
antifungal resistance [12]. More troubling is the recent emergence of multidrug-resistant (MDR)
Candida species, including C. glabrata and C. auris [13–16], the increasing trend of fluconazole-resistant
C. parapsilosis and C. tropicalis [13,17], and inherently resistant C. krusei, which notoriously affect the
efficacy of antifungal treatment.
The recent global pandemic of COVID-19 has resulted in an unprecedented 890,000 deaths
worldwide [18]. A notable proportion of COVID-19 critically ill patients develop acute respiratory
distress syndrome (ARDS), requiring intensive care unit (ICU) admission and mechanical ventilation,
which in turn predisposes them to nosocomial infections due to bacterial and fungal infections [19,20].
Understanding the burden of COVID-19 patients with secondary infections and their etiologic
agents is paramount for the optimal management of COVID-19 patients. This knowledge will help
to refine empiric antimicrobial management for patients with COVID-19 with the hope to improve
patient outcomes.
Despite the recognition that airborne Aspergillus fumigatus is increasingly recognized as an
important cause of fungal super-infections among critically ill COVID-19 patients [19], the incidence of
candidiasis has not been evaluated in this context. Indeed, the wide use of antibiotics, corticosteroids,
and central venous catheters, along with the damage exerted by SARS CoV-2 among patients with
ARDS [19], may allow commensal Candida to cells to invade internal organs [20–27]. The goals of
this manuscript are to review our current knowledge on Candida super-infections among COVID-19
patients, discuss the potential immunological and clinical factors predisposing these patients to invasive
candidiasis, and outline what studies are needed to better define the epidemiology of this superinfection.
2. Immunology
2.1. General Pathophysiology of SARS COV-2
Similar to other SARS coronaviruses, the pathophysiology of SARS-CoV-2 involves targeting and
invading epithelial cells and type II pneumocytes through the binding of the SARS spike protein to the
angiotensin-converting enzyme 2 (ACE2) receptor [28]. During the course of the host–virus interaction,
the type 2 transmembrane protease TMPRSS2 cleaves the S1/S2 domain of the viral spike protein [29]
and promotes viral entry into the target cells. ACE2 is required for protection from severe acute lung
injury in ARDS [30], and the viral-mediated manipulation of this receptor is considered one major
mechanism contributing to severe lung injury in selected COVID-19 patients. The degree of variability
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in the severity of disease is also supported, at least in part, by the existence of genetic variants that
affect the ACE2 activity and underlie an increased susceptibility to ARDS and worse prognosis [31].
Besides the implications of ACE2 in the pathogenesis of COVID-19, recent studies have also suggested
that the disruption of the renin-angiotensin system and/or the kallikrein-kinin system could contribute
to the detrimental inflammatory phenotype observed in patients with severe COVID-19 [32,33].
2.2. Does Immunity Renders Susceptibility to Invasive Yeast Infections?
Infection with SARS-CoV2 elicits an immune response that triggers an inflammatory cascade
as the result of the activity of innate immune cells. However, the dynamics of how the immune
system senses and responds to SARS-CoV-2 is just unfolding, which limits our understanding
of possible immune-mediated pathways contributing to the pathogenesis COVID-19-associated
candidiasis (CAC). Cell types important for host defense against Candida, such as neutrophils and
monocytes/macrophages, are not affected by SARS-CoV-2, suggesting that they are not responsible for
CAC. Indeed, single-cell analyses of bronchoalveolar lavages from critically ill patients with COVID-19
showed an abundance of monocyte-derived macrophages [34]. Similarly, an increased peripheral
neutrophil-to-lymphocyte ratio was also observed in severe cases of COVID-19, and was likely
associated with unfavorable prognosis [35]. While the increasing numbers (and activation profiles) of
these cells may contribute to tissue damage and the severity of disease, they are an unlikely risk factor
for invasive candidiasis. One exception is the decreased expression of human leukocyte antigen DR
on the membrane of circulating monocytes [36], which is considered a marker of immune paralysis;
however, its relevance in susceptibility to candidemia is unclear. The clear immune defect in patients
with COVID-19 is, on the other hand, lymphopenia; however, an isolated decrease in lymphocyte
numbers, as also experienced by HIV patients, is not associated with an increase in susceptibility
to systemic Candida infections. Taken together, these findings support the concept that classical risk
factors for invasive candidiasis, rather than an overt immune dysfunction, are the major drivers of
susceptibility to CAC.
3. Epidemiology of CAC, Clinical and Microbiological Factors: Current Paradigm
To obtain studies reporting yeast infections among patients with COVID-19, we included
all studies published up to September 10, 2020. Our search included yeast, Candida, COVID-19,
fungal super-infection +COVID-19, and fungal super-infections + COVID-19, and we used both the
Google and PubMed search engines. The extent of CAC (both superficial and invasive) varies by
country and region. Studies from Spain [37], India [27], Iran [22], Italy [26], the UK [23], and China [20]
have reported rates of 0.7% (7/989), 2.5% (15/596), 5% (53/ 1059), 8% (3/43), 12.6% (17/135), and 23.5%
(4/17) [20], respectively (Table 1). Although a previous study from Iran indicated a relatively low level
of oral candidiasis (OC) among patients with COVID-19 (53/1059), apparently that study included all
the patients who presented with COVID-19 but not those developing ARDS, which may have resulted
in an underestimation of OC in the context of COVID-19 [22].
J. Fungi 2020, 6, 211 4 of 13
Table 1. Clinical and microbiological features of COVID-19-associated invasive yeast infections in studies with detailed clinical and microbiological data.
Country (Case




Positivity Species (Resistance Pattern) Treatment Outcome
India (15/596; 2.5%)
[27]
25/F CLD with grade IIencephalopathy, AKD Antibiotic use, CVC, and UC 35 14 C. auris (MAR), blood culture AMB Survived
52/M HT, DM Antibiotic use, steroid therapy,CVC, and UC 20 14 and 17 C. auris (FLCR), blood culture MFG and AMB Died
82/F HT, DM, hypothoidism, ondialysis for CKD stage 5
Antibiotic use, steroid therapy,
CVC, and UC 60 42 and 47 C. auris (FLCR), blood culture MFG Died
86/F CLD, IHD, DM Antibiotic use, steroid therapy,CVC, and UC 21 10 C. auris (FLCR), blood culture MFG Died
66/M HT, DM, asthma Antibiotic use, CVC, and UC 20 11 and 15 C. auris (FLCR+AMBR),blood culture MFG and AMB Survived
71/M Hypothoidism, on dialysis forCKD stage 5
Antibiotic use, steroid therapy,
CVC, and UC 32 12 and 17 C. auris (FLCR), blood culture MFG Died
67/M HT, DM, COPD Antibiotic use, steroid therapy,CVC, and UC 21 11
C. auris (FLCR+AMBR),
blood culture AMB and MFG Survived
72/M HT, CLD Antibiotic use, steroid therapy,CVC, and UC 27 16 and 19
C. auris (MAR+AMBR),
blood culture MFG Died
81/M DM, HT, IHD Antibiotic use, steroid therapy,CVC, and UC 20 15 C. auris (MAR), blood culture MFG Died
69/M HT, asthma Antibiotic use, steroid therapy,CVC, and UC 21 14
C. auris (FLCR+AMBR),
blood culture MFG Survived
56/M HT, COPD Antibiotic use, CVC, and UC 18 7 C. tropicalis (S), blood culture MFG Survived
69/M HT, DM, obesity, IHD Antibiotic use, CVC, and UC 27 8 C. albicans (S), blood culture MFG Survived
43/F HT Antibiotic use, steroid therapy,CVC, and UC 24 12 C. albicans (S), blood culture MFG Survived
47/M Asthma, DM Antibiotic use, CVC, and UC 18 5 C. albicans (S), blood culture AMB and MFG Died
66/M HT Antibiotic use, steroid therapy,CVC, and UC 28 7 C. krusei (IFR), blood culture AMB Died
Oman (5/ ND) A
[25]
76/M None Antibiotic use, CVC ND ND C. albicans (S), CVC culture No Died
68/M HT Antibiotic use, CVC ND ND C. albicans (S), blood culture CAS + CVCremoval Died
38/M HT, dyslipidemia, old stroke Antibiotic use, CVC ND ND C. glabrata (S), blood culture MFG→CAS→AMB Died
64/M HT Antibiotic use, CVC ND ND C. albicans + C. tropicalis (S),blood culture CAS+VRC Survived
49/M None Antibiotic use, CVC ND ND C. albicans (S), blood culture CAS Survived
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Table 1. Cont.
Country (Case




Positivity Species (Resistance Pattern) Treatment Outcome
UK (17/135; 12.6%)
[23]
ND HT, obesity CVC ND ND No ID, CVC FLC Died
ND HT ND ND Rhodotorula spp., blood culture CAS, LAMB Died
ND Oseophagectomy, cancer Hydrocortisone ND ND No ID, from chest drain FLC Died
ND Ulcerative colitis CVC ND ND C. albicans, CVC None Survived
ND DM, HT, obesity, asthma CVC ND ND C. albicans, CVC FLC Survived
ND HT, asthma ND ND C. albicans, blood culture, BDG = 156,95, 86, Candida PCR = Positive CAS Survived
ND Haem, cardiac ND ND C. albicans, blood culture None Died
ND None CVC ND ND C. albicans, CVC FLC Survived
ND Cardiac, CKD, cancer CVC ND ND C. albicans, CVC CAS Died
ND Asthma, inflammatory,irritable bowel syndrome CVC ND ND C. albicans, CVC VRC Died
ND None CVC ND ND C. parapsilosis, CVC CAS Survived
ND None CVC ND ND C. albicans, CVC and blood culture FLC Died
ND None ND ND C. albicans, blood culture, BDG > 500,Candida PCR = Positive FLC, CAS Survived
ND DM, HT, Obesity CVC ND ND C. albicans, CVC FLC Survived
ND Hepatitis, intravenous druguser, neutropenia, cellulitis ND ND
C. albicans + C. parapsilosis, blood
culture, BDG = 386 FLC, LAMB Survived
ND DM, inflammatory, alcoholic Steroid therapy (ND) ND ND C. albicans, ascites culture CAS, VRC Survived
ND DM, HT ND ND C. albicans, CVC, BDG > 500 FLC, VRC Died
Italy (3/43; 8%) [26]
67/M Cerebral ischemia Parentral nutrition, antibiotic use,CVC, and Tocilizumab (8 mg/kg) ND 13 C. albicans, blood culture CAS+FLC Survived
58/M HT Parenteral nutrition andTocilizumab (8 mg/kg) ND 17 C. tropicalis, blood culture CAS Survived
78/M DM and obesity
Parenteral nutrition, antibiotic
use, steroid therapy, CVC, and
Tocilizumab (8 mg/kg)
ND 13 C. parapsilosis, blood culture CAS+FLC Survived
Italy (1/ND) [24] 79/M DM, IHD, stadium IVperipheral artery disease Antibiotic use and surgery 35 53 C. glabrata (PER), blood culture CAS Died
Greece (2/ND) [21]
76/M HT Antibiotic use, Ultra-Levure(250–500 mg/day) 80
35 (4 days after
Ultra-Levure) S. cerevisiae (S), blood culture AND→FLC Survived
73/M HT and DM Antibiotic use, Ultra-Levure(250–500 mg/day)
Transferred to a
regional hospital
15 (6 days after
Ultra-Levure) S. cerevisiae (S), blood culture AND→FLC Survived
A. The total number of severely ill patients was not determined for studies from Italy [24], Greece [21], and Oman [25]. AKD: Acute kidney disease; CKD: Chronic kidney disease; CLD: Chronic
liver disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HT: Hypertension; IHD: Ischemic heart diseases; CVC: Central venous catheter; UC: Urinary
catheter; AMB: Amphotericin B; LAMB: Liposomal AMB; MFG: Micafungin; CAS: Caspofungin; VRC: Voriconazole; FLC: Fluconazole; S: Susceptible; FLCR: Fluconazole-resistant;
AMBR: Amphotericin B-resistant; IFR: Intrinsically fluconazole-resistant MAR: Multiazole-resistant; MDR: Multidrug-resistant; PER: Pan-echinocandin-resistant; ND: Not determined;
PCR: Polymerase chain reaction; BDG: Beta-d-glucan.
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A study from Spain reported a rate of 0.7% (7/989) of fungal super-infections complicating
hospitalized COVID-19 patients: four were caused by molds and three by Candida (one each of
candidemia, candiduria, and complicated intraabdominal candidiasis (IAC)) [37]. Similarly, a recent
study from the UK reported a similar prevalence of invasive yeast infections and invasive pulmonary
aspergillosis (12.6% vs. 14.1%) among COVID-19 patients who presented with ARDS [23]. A study from
Greece reported that two COVID-19 patients residing in an ICU developed bloodstream infection due
to Saccharomyces cerevisiae a few days (4–6 days) after receiving a probiotic supplement (Ultra-Levure)
which contains this yeast. Interestingly, none of the 320 patients admitted to the same unit in the previous
4 years developed S. cerevisiae fungemia while receiving the same probiotic [21]. This observation,
while anecdotal, suggests that the sepsis syndrome or septic shock associated with severe COVID-19
may damage the intestinal mucosal barrier, enabling the translocation of concentrated fungus in
probiotics (250–500 mg/day in this case), leading to fungemia [38,39]. This study cautions about the
routine use of prophylactic probiotics among critically ill COVID-19 cases in the ICU setting.
Moreover, a recent study from Italy also reported three candidemia cases among critically ill
COVID-19 patients following treatment with tocilizumab, an IL-6 receptor monoclonal blocking
agent [26]. Central venous catheterization (CVC) (32/43; 74.5%), antibiotics (26/43; 60.5%), and steroid
therapy use (13/43; 13.2%) were among the most prominent risk factors reported (Table 1).
Overall, the mortality rate of invasive Candida infections was approximately 46% (20/ 43), which
varied depending on the species and the antifungal used to treat invasive yeast infections. Indeed,
this mortality rate is presumably higher than that of severely ill patients with COVID-19, ranging
between 25.8% [40] and 30.9% [41]. Per species, the mortality rate was the highest for patients infected
with C. glabrata (2/2; 100%), C. auris (6/10; 60%), and C. albicans (8/19; 42%), while those treated with
C. tropicalis, C. parapsilosis, and multiple Candida species all survived (two patients infected with
C. krusei and Rhodotorula spp. and two with unknown species also died). It is noteworthy that those
results may be misleading due to the limited numbers, since C. tropicalis has been shown before to be
associated with the poorest prognosis and also carries a high rate of mortality when compared to other
non-Candida albicans Candida species [42,43].
According to recent studies detailing invasive yeast infections among critically ill COVID-19
patients (21, 23–27), C. albicans (19/43; 44.1%) was shown to be the most prevalent yeast species,
followed by C. auris (10/43; 23.2%); C. glabrata, C. parapsilosis, C. tropicalis, and S. cerevisiae (2/43; 4.6%
each); and C. krusei and Rhodotorula spp. (1/43; 2.3% each). Of note, there was no species identity
reported for two yeast isolates obtained from catheter and chest drain, and two patients had mixed
invasive yeast infections caused by C. albicans + C. parapsilosis and C. albicans + C. tropicalis (Table 1).
Importantly, C. auris was the most prevalent Candida species from the Indian study, while C. albicans
was the most prevalent in the other studies. Where antifungal susceptibility testing was performed,
the resistance patterns varied depending on the species. For instance, resistance to fluconazole,
multiple azoles (fluconazole and voriconazole), and multidrugs (fluconazole and AMB) was noted
for 100%, 30%, and 40% of the C. auris isolates, respectively, and only one C. glabrata isolate was
echinocandin-resistant (Table 1). Persistent invasive yeast infections have been noted during the course
of antifungal therapy, while the yeasts isolated showed susceptible profiles to the antifungal used for
treatment [25,27]. Most notably, 67% of the patients who died with invasive yeast infections due to
C. auris showed persistent candidemia, despite being treated with micafungin [27] in the absence of
resistance, which might be explained by other host and pathogen-related factors [44–46]. Therefore,
these data highlight the urgency of conducting comprehensive studies elucidating the real burden of
each entity among COVID-19 cases manifesting ARDS.
4. Risk Factors
The risk factors for CAC can be divided into two groups. The first group includes common risk
factors predisposing ICU patients to invasive candidiasis. These include diabetes mellitus, renal failure
requiring hemodialysis, abdominal surgery, triple lumen catheters, parenteral nutrition, receipt of
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multiple antibiotics, length of ICU stay >7 days, and prior abdominal infections [10,47,48]. Additionally,
indwelling central venous catheters are widely used among COVID-19 patients residing in ICUs [49].
Indeed, catheters are historically known as a portal of entry for acquiring nosocomial Candida
infections, such as Candida auris and C. parapsilosis [15,16,50,51]. Of note, approximately 82% of
CVC-recovered yeast isolates were C. albicans (9/ 11) (Table 1), which also shows that other Candida
species have the potential to cause CVC-related invasive yeast infections. Unlike endogenously acquired
Candida species, such as C. glabrata, that require previous exposure to antifungals drugs to become
drug-resistant, drug-resistant C. auris and C. parapsilosis can persist on the hospital environments,
devices, and hands of healthcare workers and subsequently cause drug-resistant candidiasis and/or
candidemia among antifungal-naïve patients [15–17,50–53]. It is also noteworthy that some studies
have found an association between antibiotic use and the emergence of candidemia due to Candida
species exhibiting a high minimum inhibitory concentration (MIC) and/or intrinsic resistance to
fluconazole [54,55]. Furthermore, the development of invasive candidiasis is often preceded by the
Candida colonization of the skin and mucous membrane. Candida colonization at multiple body sites is
a strong predictor of invasive candidiasis [56]. Along the same line, the Candida colonization of the
airway has been observed in 20% of patients after 48 h of being on mechanical ventilation, and the
longer the duration of ventilation, the higher the colonization rate [3]. Up to 94% of hospitalized
patients with COVID-19 receive antimicrobial agents [57–59], and this might further heighten the
Candida colonization rate. Patients with sepsis or septic shock, commonly observed in severe COVID-19
patients in the ICU, may develop a leaky gut that facilitates Candida translocation from the GI tract into
systemic circulation [39,60–62].
The second group of risk factors are more specifically associated with COVID-19. First, patients with
severe respiratory failure associated with COVID-19 might require extracorporeal membrane
oxygenation (ECMO) [63]. ECMO involves a higher number of vascular catheters (pulmonary and
peripheral arterial catheters and ECMO cannula in addition to central venous catheters). ECMO is also
associated with a clotting tendency that facilitates microbial pathogen (bacteria and fungus) adhesion to
the catheters, as well as leukopenia that results from the sequestration of leukocytes in the lung capillaries
and peripheral tissues, and adhesion to and lysis of leukocytes by ECMO circuit. ECMO cannula
are often colonized by skin commensals such as Candida and coagulase-negative Staphylococcus, a
condition that predisposes one to bloodstream infection. Altogether, these risk factors predispose one
to systemic infection. Second, corticosteroids have been increasingly used among hospitalized patients
with COVID-19 [19]. Corticosteroids have immunosuppressive effects on neutrophils, monocytesm
and macrophages and predispose patients to invasive candidiasis. Lastly, whether the severe lung
epithelium damage exerted by SARS CoV-2 facilitates Candida adherence to basement membrane causing
subsequent invasive pulmonary candidiasis is not known. To date, primary Candida pneumonitis is
considered to be rare.
5. Diagnosis
The diagnosis of candidemia and other forms of invasive candidiasis remains challenging, which is
mostly due to the low number of yeast cells in circulation or infected tissue [64], a requirement of
an invasive procedure for diagnosing deep-seated candidiasis, and the use of non-fungal-specific
media to culture clinical samples [65]. While culture remains the gold standard, approximately 50%
of the invasive candidiasis are not identified by blood culture, and the application of non-culture
diagnostics—i.e., β-D-Glucan (BDG) and mannan antigen testing, and molecular platforms such
as PCR and T2 Candida panel—are recommended to improve the diagnosis [64]. BDG (Associates
of Cape Cod Diagnostics; MA, USA) is a panfungal marker and therefore a positive result is not
specific for invasive candidiasis. The sensitivity and specificity for diagnosing invasive candidiasis
are around 80% [66,67], and can further be increased when combined with procalcitonin, which may
help to differentiate fungal from bacterial infections [68], but false positive results have been described,
in particular in conditions associated with fungal translocation in the gut, such as sepsis or advanced
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liver cirrhosis [61,69]. BDG results should therefore be carefully evaluated and always interpreted
with other clinical data. Importantly, serum BDG has been shown to be a reliable tool for antifungal
stewardship, and has a high negative predictive value for invasive Candida infections, allowing for the
early discontinuation of empirical antifungal therapy if tested from samples drawn before treatment
initiation [70,71]. Enzyme-linked immunosorbent assay (ELISA) kits for the detection of Candida
mannan antigen are commercially available to detect Candida in serum samples for the diagnosis
of invasive candidiasis (Platelia™ Candida Ag, Bio-Rad), and are associated with a relatively high
specificity and sensitivity [72]. In a recent meta-analysis, blood PCR was associated with a pooled
sensitivity and specificity for proven or probable invasive candidiasis vs. at-risk controls of 95% and
92%, respectively [73]. The recently developed T2Candida Panel (T2Biosystems) combines ITS2 region
amplification and T2 magnetic resonance, and can directly detect Candida spp. in EDTA blood samples
within 5 h and has proved efficient for the diagnosis of candidemia and intra-abdominal candidiasis,
although the technical demands can be a drawback [74–76].
Combining multiple techniques is recommended in order to improve the sensitivity of the
techniques [64,77,78]. However, while serum BDG testing and screening has been used successfully
in COVID-19 patients for the detection of COVID associated aspergillosis [19], the utility of other
techniques remains to be determined in the context of COVID-19 patients with ARDS.
6. Treatment and Future Directions
Since invasive yeast infections are associated with a higher mortality in COVID-19 cases not
receiving antifungal treatment compared to those receiving it [23], prompt diagnosis and treatment is of
paramount importance to achieve clinical success. The management of invasive candidiasis in patients
with COVID-19 is similar to that of non-COVID-19 patients. Echinocandins are the treatment of choice for
invasive Candida infections, with fluconazole, liposomal amphotericin B, voriconazole, posaconazolem
and isavuconazole being the second line alternatives [79–81]. Source control, including, if feasible,
the removal of central venous catheters in candidemic patients, is a major determinant factor of the
outcome. Echinocandins are usually well tolerated and have a favorable pharmacokinetic (PK) profile,
with very few drug–drug interactions [82]. A major drawback of echinocandins is their intravenous
formulation. While not impacting most hospitalized and ICU patients, it is a factor for step-down
therapy or prophylaxis. The triterpenoid ibrexafungerp is a new class of structurally distinct glucan
synthase inhibitors, which is currently being evaluated in various phase III trials, showing an excellent
bioavailability after oral intake [83]. Moreover, the penetration of currently available echinocandins
into the abdominal infection site might not be optimal, and the emergence of echinocandin-resistant
Candida isolates during treatment, especially C. glabrata, is problematic [44,84]. The newer generation
of echinocandins, such as the long PK and the once-weekly drug rezafungin, have shown a favorable
penetration in models of IAC when compared to other echinocandins [84]. Another novel antifungal in
the pipeline that will likely advance the management of invasive candida infections in the near future
is fosmanogepix. It has a novel mechanism of action that inhibits the highly conserved fungal enzyme
Gwt1, which is essential for the biosynthesis of glycosylphosphatidylinositol anchors.
Among patients with septic shock attributed to invasive candidiasis, the timely administration
of antifungal therapy is paramount for a favorable outcome. Consistent with the data described in
this overview, we need to increase our efforts to understand the full extent of this invasive fungal
complication in COVID-19, and to design the best diagnosis and therapy. What should be done in the
future? Since blood culture has a poor sensitivity and delayed turnaround time, the development of
predictive scores or diagnostic tests that yield high positive and/ or negative predictive values is sorely
needed. Diagnostics directly from blood may offer the fastest laboratory results for high-risk patients.
Among COVID-19 patients, the incidence of super-infections due to Candida is currently not known.
It is also unknown whether Candida super-infection leads to excess mortality or if it is merely a marker
of the severity of COVID-19 infection. Well-designed and careful epidemiologic studies are needed to
define the true burden of invasive candidiasis among patients with COVID-19. Prospective studies
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that include systematic blood and other biological sample collection might enhance future research in
invasive Candida infections.
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